FDC · NSE
FDC Limited
₹352.5
+0.10% (+₹0.35)
Prev. close
₹352.15
Volume
1,15,044
Delivery %
60.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About FDC Limited
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastroenterology, ophthalmology, anti-diabetics, cardiovascular care, respiratory care, gynaecology, dermatology, paediatrics, analgesics, vitamins, and nutritional health in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured oral rehydration solution powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zifi-0, Zocon, Mycoderm, Zathrin, Victofol, Cotaryl, Ziglim-M, Amodep-AT, MumMum 1, Victofol Injection, Simyl MCT, Victofol C, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ameya Ashok Chandavarkar
Headquarters
Mumbai
Employees
7,076
Website
fdcindia.comExchange
View on NSE ↗Key stats
Market cap
₹5,739.06 Cr
P/E ratio (TTM)
19.6
Dividend yield
2.84%
EPS (TTM)
₹17.99
Beta (1Y · daily vs NIFTY 50)
0.44
Beta (5Y · monthly vs NIFTY 50)
1.09
Shares float
6.92 Cr
EPS · quarter ended Jun 2026
₹8.14
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,333.20 Cr | ₹1,527.92 Cr | ₹1,783.75 Cr | ₹1,942.94 Cr | ₹2,102.57 Cr | ₹2,170.93 Cr | |
| EBITDA | ₹428.95 Cr | ₹329.78 Cr | ₹300.83 Cr | ₹440.17 Cr | ₹414.68 Cr | ₹438.83 Cr |
| ₹301.35 Cr | ₹216.00 Cr | ₹194.04 Cr | ₹305.22 Cr | ₹266.79 Cr | ₹281.42 Cr | |
| Diluted EPS | ₹17.72 | ₹12.81 | ₹11.66 | ₹18.58 | ₹16.39 | ₹17.29 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,956.00 Cr | ₹2,270.00 Cr | ₹2,343.00 Cr | ₹2,468.00 Cr | ₹2,714.00 Cr | ₹2,919.00 Cr | |
| ₹14.66 Cr | ₹32.20 Cr | ₹28.32 Cr | ₹20.52 Cr | ₹21.17 Cr | ₹15.47 Cr | |
| Stockholders' equity | ₹1,734.00 Cr | ₹1,957.00 Cr | ₹1,982.00 Cr | ₹2,097.00 Cr | ₹2,281.00 Cr | ₹2,485.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹207.00 Cr | ₹162.00 Cr | ₹155.00 Cr | ₹221.00 Cr | ₹318.00 Cr | ₹200.00 Cr | |
| Investing cash flow | ₹-77.15 Cr | ₹-144.57 Cr | ₹11.13 Cr | ₹-17.08 Cr | ₹-199.51 Cr | ₹-109.93 Cr |
| ₹-129.00 Cr | ₹-10.00 Cr | ₹-180.00 Cr | ₹-202.00 Cr | ₹-92.00 Cr | ₹-93.00 Cr | |
| Capital expenditure | ₹-63.00 Cr | ₹-133.00 Cr | ₹-113.00 Cr | ₹-93.00 Cr | ₹-97.00 Cr | ₹-187.00 Cr |
| End cash position | ₹30.43 Cr | ₹37.73 Cr | ₹23.89 Cr | ₹25.42 Cr | ₹51.47 Cr | ₹48.68 Cr |
Debt repaid has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22–Jun 23(5Q) | Sep 23–Jun 26(12Q) |
|---|---|---|---|---|
| Promoter | 69.35% | 69.36% | 69.50% | 69.66% |
| Public | 30.65% | 30.64% | 30.50% | 30.34% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| FDC Limited | ₹5,701.61 Cr | ₹352.15 | 19.5 | 2.29 | 11.3% | 0.01 | +2.9% | -25.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
8 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.